Atrial Fibrillation and Stroke Prevention
Atrial fibrillation (AF) affects over 30 million people worldwide and carries a five-fold increased stroke risk, accounting for 20–30% of all ischemic strokes — typically more severe with worse outcomes than other etiologies. The AF management landscape has evolved substantially with advances in rhythm monitoring, novel anticoagulants, left atrial appendage closure devices, and catheter ablation. Recent trials have clarified the management of subclinical AF, alternatives to anticoagulation, and whether anticoagulation can be safely discontinued after successful ablation.
🔹 Bottom Line: Atrial Fibrillation and Stroke
- Clinical AF: Anticoagulate if CHA₂DS₂-VASc ≥2; DOACs preferred over warfarin
- SCAF ≥24 hours: Treat like clinical AF — anticoagulation recommended
- SCAF 6 min – 24 hours: DOAC reduced stroke by about 40% however incidence of major bleeding has increased, decision for anticoagulation should be individualized(ARTESiA)
- SCAF ≥6 minutes with history of embolic stroke: Most neurologists would start on DOAC. ARTESIA subgroup analysis shows stroke risk reduction from 3.14% to 1.2%.
- LAAO: Reasonable alternative if contraindication to long-term anticoagulation
- Post-ablation: for patients without AF recurrence ≥1 year and low-to-moderate stroke risk, discontinuation may be safe (ALONE-AF, OCEAN)
Definitions and Classification
The terminology around AF has evolved with the proliferation of cardiac monitoring devices. Whether AF is clinical or not, is not based on symptoms, it is based on recording method, surface or implantable.
Clinical AF
Clinical atrial fibrillation is defined as AF documented on a surface ECG (12-lead or Holter or Event monitor of ≥30 seconds). This is the traditional definition used in landmark anticoagulation trials and guideline recommendations.
| Pattern | Definition | Clinical Implications |
|---|---|---|
| Paroxysmal AF | AF that terminates spontaneously or with intervention within 7 days | Same stroke risk as persistent AF; anticoagulation based on CHA₂DS₂-VASc |
| Persistent AF | AF lasting >7 days, including episodes terminated by cardioversion after ≥7 days | May benefit from rhythm control strategy |
| Long-standing persistent | Continuous AF >12 months when rhythm control strategy is pursued | Lower success rates with ablation |
| Permanent AF | AF accepted by patient and physician; no further attempts at rhythm control | Rate control focus; anticoagulation continues |
Subclinical AF (SCAF) and Device-Detected AF
Subclinical atrial fibrillation (SCAF) refers to AF detected by implantable (e.g., loop recorder, pacemaker, ICD) or wearable monitors (e.g., smartwatch rhythm alerts), that has not been documented on a standard ECG.
Atrial high-rate episodes (AHREs) are a related but distinct entity — rapid atrial activity (typically >175-190 bpm for >5-6 minutes) detected by cardiac implantable electronic devices (CIEDs). Not all AHREs represent true AF; some are atrial flutter, atrial tachycardia, or artifact. Visual review of device electrograms is needed to confirm SCAF.
| Term | Definition | Detection Method |
|---|---|---|
| Clinical AF | AF documented on surface ECG ≥30 seconds | 12-lead ECG, Holter, event monitor |
| SCAF | AF detected without surface ECG | Pacemaker, ICD, ILR, wearables |
| AHRE | Atrial rate >175-190 bpm for >5-6 min (CIED-detected) | Pacemaker, ICD with atrial lead |
SCAF is common — detected in ~25-30% of patients with CIEDs — and tends to progress to clinical AF at a rate of ~10% per year. The key clinical question is whether SCAF carries the same stroke risk as clinical AF and whether anticoagulation provides net benefit.
Clinical AF: When to Anticoagulate
For patients with clinical AF, the decision to anticoagulate is based on stroke risk assessment using validated scores. The 2023 ACC/AHA/ACCP/HRS and 2024 ESC guidelines provide clear recommendations.
- CHA₂DS₂-VASc ≥2: Oral anticoagulation recommended (Class I)
- CHA₂DS₂-VASc 1: Anticoagulation should be considered (Class IIa)
- CHA₂DS₂-VASc 0 (men) or 1 (women without other risk factors): Anticoagulation not required
- DOACs preferred over warfarin (except mechanical valves, AF associated with moderate-severe mitral stenosis)
Anticoagulation Recommendations
CHA₂DS₂-VASc Score
| Risk Factor | Points |
|---|---|
| Congestive heart failure | 1 |
| Hypertension | 1 |
| Age ≥75 years | 2 |
| Diabetes mellitus | 1 |
| Stroke/TIA/thromboembolism | 2 |
| Vascular disease (MI, PAD, aortic plaque) | 1 |
| Age 65-74 years | 1 |
| Sex category (female) | 1 |
Note: The 2024 ESC guidelines use CHA₂DS₂-VA (excluding sex as a modifier), arguing that female sex alone does not increase stroke risk in the absence of other factors.
🔹 Risk Modifiers Beyond CHA₂DS₂-VASc
For patients at intermediate risk (CHA₂DS₂-VASc 1-2), additional factors may inform shared decision-making:
- Higher AF burden (persistent/permanent > paroxysmal)
- Poorly controlled hypertension
- Hypertrophic cardiomyopathy or cardiac amyloidosis
- CKD (eGFR <45 mL/min) or proteinuria
- Enlarged left atrium (≥4.7 cm or ≥73 mL)
- Obesity
Subclinical AF: When to Anticoagulate
The management of SCAF is still a debated topic. Several trials have studies anticoagulation for primary prevention of stroke in this population, but not secondary prevention (those was had embolic stroke or TIA). The landmark ASSERT trial established that device-detected episodes ≥6 minutes are associated with a 2.5-fold increased stroke risk. However, the absolute risk is lower than clinical AF, and the temporal relationship between SCAF episodes and stroke is inconsistent
Three major randomized trials have now addressed whether anticoagulation benefits SCAF patients:
Subclinical AF: Primary Stroke Prevention
NOAH-AFNET 6 (2023) randomized 2,536 patients with device-detected AHREs (≥6 minutes, no prior clinical AF) to edoxaban versus placebo. The trial was stopped early for futility: the primary endpoint (CV death, stroke, SE) was not significantly reduced (3.2% vs 4.0%/year, HR 0.81, p=0.15), while major bleeding doubled (2.1% vs 1.0%, HR 2.10, p=0.002). Subgroup analysis suggested potential benefit in patients with longer episode durations.
LOOP (2021) tested whether systematic AF screening using implantable loop recorders would reduce stroke in 6,004 high-risk patients (age 70–90, ≥1 stroke risk factor). Although ILR screening tripled AF detection (31.8% vs 12.2%) and more than doubled anticoagulation initiation (29.7% vs 13.1%), stroke rates were not significantly reduced (4.5% vs 5.6%, HR 0.80, p=0.11) — suggesting that simply detecting and treating more short-duration SCAF does not meaningfully reduce population stroke risk.
ARTESiA (2024) randomized 4,012 patients with device-detected SCAF (6 minutes to 24 hours) and CHA₂DS₂-VASc ≥3 to apixaban versus aspirin. Apixaban significantly reduced stroke/SE (0.78% vs 1.24%/year, HR 0.63, p=0.007) but increased major bleeding (1.71% vs 0.94%/year, HR 1.80, p<0.001). The net clinical benefit was modest: NNT ~250/year to prevent one stroke versus NNH ~130/year for one major bleed.
Subclinical AF: Secondary Stroke Prevention
A prespecified subgroup analysis of ARTESiA examined 346 patients (8.6%) with prior stroke or TIA. In this secondary prevention population, apixaban showed a much larger benefit: stroke/SE 1.20% vs 3.14%/year (HR 0.40, 95% CI 0.17–0.95), with 7% absolute risk reduction at 3.5 years compared to only 1% in primary prevention. Major bleeding was numerically higher but not significant (HR 1.94). In secondary prevention, anticoagulation benefit clearly outweighs bleeding risk.
🔹 Clinical Relevance: SCAF Management
Primary Prevention (No Prior Stroke/TIA):
- SCAF 6 min – 24 hours: Anticoagulation debatable; individualize based on CHA₂DS₂-VASc score, bleeding risk, and patient preference (ARTESiA showed benefit but also increased bleeding)
- SCAF ≥24 hours: Risk approaches clinical AF; most clinicians would anticoagulate
- Short, infrequent episodes in low-risk patients: Anticoagulation may not provide net benefit
- Monitor for progression: ~50% of SCAF patients progress to higher burden; ~10%/year develop clinical AF
Secondary Prevention (Prior Embolic Stroke or TIA):
- Any SCAF duration (≥6 min): Most neurologists would anticoagulate — ARTESiA subgroup showed 60% relative risk reduction (HR 0.40) and 7% absolute risk reduction at 3.5 years
Trial Comparison: Subclinical AF
| Trial | Year | N | SCAF Duration | Comparison | Key Finding |
|---|---|---|---|---|---|
| ASSERT | 2012 | 2,580 | ≥6 min | Observational | SCAF associated with 2.5× stroke risk |
| LOOP | 2021 | 6,004 | ≥6 min | ILR screening vs usual care | Screening ↑ detection but no stroke reduction |
| NOAH-AFNET 6 | 2023 | 2,536 | ≥6 min (no upper limit) | Edoxaban vs placebo | No benefit; ↑ bleeding; stopped early |
| ARTESiA | 2024 | 4,012 | 6 min – 24 h | Apixaban vs aspirin | ↓ stroke (HR 0.63); ↑ bleeding (HR 1.80) |
Alternatives to Anticoagulation: Left Atrial Appendage Occlusion
The left atrial appendage (LAA) is the source of >90% of thrombi in non-valvular AF. Left atrial appendage occlusion (LAAO) provides an alternative stroke prevention strategy, particularly for patients with contraindications to long-term anticoagulation.
Device Options
- Watchman / Watchman FLX (Boston Scientific) — most studied; FDA approved
- Amulet (Abbott) — dual-seal design; FDA approved
- Surgical LAAO — performed during cardiac surgery (LAAOS III showed 33% stroke reduction)
Evidence for LAAO
PROTECT AF (2014) and PREVAIL (2014) established non-inferiority of Watchman to warfarin for stroke prevention. Long-term follow-up showed reduced hemorrhagic stroke and CV mortality with LAAO.
PRAGUE-17 (2020) compared LAAO to DOACs in high-risk patients. LAAO was non-inferior for the composite of stroke/TIA, CV death, and bleeding (10.99% vs 13.42%/year, HR 0.84).
Amulet IDE (2021) compared Amulet to Watchman directly. Both devices showed similar safety and efficacy; Amulet achieved higher rates of complete LAA occlusion (98.9% vs 96.8%).
CLOSURE-AF (2025) randomized 912 patients at very high risk of both stroke (CHA₂DS₂-VASc ≥2) and bleeding (HAS-BLED ≥3, prior major bleeding, or CKD with eGFR 15–29) to LAAO versus best medical therapy. The primary endpoint (stroke, SE, CV/unexplained death, or major bleeding) was higher in the LAAO arm — non-inferiority not met — with excess events driven by periprocedural bleeding and CV death. This challenges the traditional indication for LAAO, suggesting very high-bleeding-risk patients may not be optimal candidates.
LAAO After Ablation: OPTION Trial (2024)
OPTION (2024) randomized 1,600 patients undergoing AF ablation to concomitant/sequential LAAO versus continued OAC. At 3 years, LAAO was non-inferior for the primary efficacy endpoint (death, stroke, SE: 5.3% vs 5.8%) and superior for non-procedural bleeding (8.5% vs 18.1%, p<0.001). Including procedural events, major bleeding remained non-inferior (3.9% vs 5.0%). This supports LAAO as a reasonable alternative to long-term anticoagulation in post-ablation patients.
🔹 Clinical Relevance: LAAO Indications
- Established indication: CHA₂DS₂-VASc ≥2 with contraindication to long-term OAC (Class IIa)
- Emerging indication: High bleeding risk on OAC (Class IIb); concomitant with AF ablation
- Post-procedure: Short-term anticoagulation (45-90 days) followed by antiplatelet therapy; DOAC alone (without aspirin) associated with lower bleeding than DOAC + aspirin
- Peri-device leak: >5mm leak associated with increased thromboembolism; may require continued anticoagulation
Anticoagulation After AF Ablation
Catheter ablation has become first-line therapy for symptomatic AF in many patients. A key question is whether successful ablation — with maintenance of sinus rhythm — eliminates the need for long-term anticoagulation.
Current Guidelines
Both the 2023 ACC/AHA/ACCP/HRS and 2024 ESC guidelines recommend:
- Continue OAC for ≥2 months post-ablation regardless of stroke risk (blanking period with high thrombotic risk)
- Long-term OAC decision based on CHA₂DS₂-VASc, independent of ablation success or rhythm outcome
- The rationale: AF may recur silently; ablation does not eliminate atrial substrate
Emerging Evidence: Can We Stop Anticoagulation?
Two recent trials challenge the dogma of indefinite anticoagulation after successful ablation:
ALONE-AF (2025)
ALONE-AF randomized 840 patients (mean age 64, CHA₂DS₂-VASc 2.1) who underwent successful AF ablation and had no AF recurrence for ≥1 year (confirmed by monitoring) to discontinue versus continue DOAC therapy:
- Primary endpoint (stroke, SE, major bleeding): 0.3% (discontinue) vs 2.2% (continue) — absolute difference -1.9%, p=0.02
- Ischemic stroke: 0.3% vs 0.8%
- Major bleeding: 0% vs 1.4%
Key findings: Stopping anticoagulation was not only non-inferior but associated with better outcomes due to elimination of bleeding risk without increased stroke.
OCEAN (2025)
OCEAN randomized 1,284 patients (mean age 66, CHA₂DS₂-VASc 2.2) at least 1 year post-successful ablation to aspirin versus rivaroxaban 15 mg. MRI was performed at baseline and 3 years:
- Primary endpoint (stroke, SE, covert embolic stroke on MRI): Similar in both groups
- Clinical stroke/SE: Low in both arms (~1.2-1.3%)
- Interpretation: Aspirin provides similar stroke protection to rivaroxaban in successfully ablated patients with low-to-moderate stroke risk
🔹 Clinical Relevance: Post-Ablation Anticoagulation
- Continue OAC for ≥2 months after ablation (blanking period)
- Patients with AF recurrence: Continue anticoagulation based on CHA₂DS₂-VASc
- No AF recurrence for ≥1 year + low-to-moderate stroke risk (CHA₂DS₂-VASc 1-3): Discontinuation may be safe (ALONE-AF, OCEAN); shared decision-making
- High stroke risk (CHA₂DS₂-VASc ≥4) or prior stroke: Insufficient evidence to stop OAC; consider continued therapy or LAAO
- Monitoring essential: Patients must have confirmed sinus rhythm maintenance; silent AF recurrence is common
Trial Comparison: Anticoagulation After Ablation
| Trial | Year | N | Population | Comparison | Key Finding |
|---|---|---|---|---|---|
| OPTION | 2024 | 1,600 | AF ablation patients | LAAO vs OAC | LAAO non-inferior; superior for non-procedural bleeding |
| ALONE-AF | 2025 | 840 | No AF recurrence ≥1 year post-ablation | Stop vs continue DOAC | Stop superior (0.3% vs 2.2%); no ↑ stroke, ↓ bleeding |
| OCEAN | 2025 | 1,284 | Successful ablation ≥1 year | Aspirin vs rivaroxaban | Similar outcomes; supports de-escalation |
Factor XIa Inhibitors:
Factor XIa inhibitors were hypothesized to provide stroke prevention with less bleeding than traditional anticoagulants. OCEANIC-AF (2025) tested asundexian (a factor XIa inhibitor) versus apixaban in AF patients. The trial was stopped early due to harm:
- Stroke/SE: 1.3% (asundexian) vs 0.4% (apixaban) — HR 3.79
- Major bleeding: 0.2% vs 0.7% — HR 0.32 (less bleeding, but more stroke)
- Net clinical benefit: Worse with asundexian (1.6% vs 1.0%, HR 1.61)
Factor XIa inhibition does not provide adequate stroke protection in AF patients. DOACs remain the standard.
Summary: Treatment Algorithm
| Scenario | Recommendation |
|---|---|
| Clinical AF, CHA₂DS₂-VASc ≥2 | Anticoagulation, DOAC is preferred |
| Clinical AF, CHA₂DS₂-VASc 1 | Consider anticoagulation; use risk modifiers |
| Subclinical AF (SCAF) | |
| + Prior embolic stroke/TIA | Anticoagulate — benefit outweighs risk |
| ≥24 hours (no prior stroke) | Treat as clinical AF — anticoagulate per CHA₂DS₂-VASc |
| 6 min – 24 hours, high risk (no prior stroke) | Individualized; no strong evidence for routine OAC |
| 6 min – 24 hours, low risk | Monitor for progression; OAC unlikely to provide net benefit |
| Contraindication to long-term OAC | Consider LAAO (Class IIa) |
| Post-ablation, high risk | Consider OAC continuation |
| Post-ablation, no recurrence ≥1 year, low-moderate risk | Discontinuation may be safe; shared decision |
References
- Healey JS, et al. Subclinical atrial fibrillation and the risk of stroke (ASSERT). N Engl J Med. 2012;366:120-129.
- Svendsen JH, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (LOOP). Lancet. 2021;398:1507-1516.
- Kirchhof P, et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes (NOAH-AFNET 6). N Engl J Med. 2023;389:1167-1179.
- Healey JS, et al. Apixaban for stroke prevention in subclinical atrial fibrillation (ARTESiA). N Engl J Med. 2024;390:107-117.
- Holmes DR, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke (PROTECT AF). Lancet. 2014;384:449-456.
- Holmes DR Jr, et al. Prospective randomized evaluation of the Watchman LAA closure device (PREVAIL). J Am Coll Cardiol. 2014;64:1-12.
- Osmancik P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with AF (PRAGUE-17). J Am Coll Cardiol. 2020;75:3122-3135.
- Lakkireddy D, et al. Amplatzer Amulet left atrial appendage occluder versus Watchman device (Amulet IDE). Circulation. 2021;144:1543-1552.
- Piccini JP, et al. Asundexian versus apixaban in atrial fibrillation (OCEANIC-AF). N Engl J Med. 2025.
- Choi JI, et al. Discontinuation of anticoagulant therapy after catheter ablation for atrial fibrillation (ALONE-AF). JAMA. 2025.
- Verma A, et al. Antithrombotic therapy after successful catheter ablation for atrial fibrillation (OCEAN). N Engl J Med. 2025.
- Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation. 2024;149:e1-e156.
- Van Gelder IC, et al. 2024 ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2024;45:3314-3414.